11/14
04:05 pm
alms
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Medium
Report
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
11/14
09:06 am
alms
Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/14
08:15 am
alms
Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $30.00 to $26.00. They now have a "buy" rating on the stock.
High
Report
Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $30.00 to $26.00. They now have a "buy" rating on the stock.
11/13
04:22 pm
alms
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
High
Report
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
11/13
04:05 pm
alms
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
High
Report
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
11/4
08:00 am
alms
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Low
Report
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
11/1
07:23 am
alms
Alumis Inc. (NASDAQ: ALMS) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Low
Report
Alumis Inc. (NASDAQ: ALMS) was upgraded by analysts at Baird R W to a "strong-buy" rating.
10/31
07:36 am
alms
Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $25.00 price target on the stock.
Low
Report
Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $25.00 price target on the stock.
10/17
08:13 am
alms
Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
Alumis Inc. (NASDAQ: ALMS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
9/27
09:00 am
alms
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Medium
Report
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
9/4
04:14 pm
alms
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch [Yahoo! Finance]
Low
Report
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch [Yahoo! Finance]
9/3
04:29 pm
alms
Alumis to Participate in Upcoming September Investor Conferences
Low
Report
Alumis to Participate in Upcoming September Investor Conferences